**Background of GOT1 Antibody**
The GOT1 (Glutamic-Oxaloacetic Transaminase 1) antibody is a tool used to detect and study the GOT1 protein, also known as aspartate aminotransferase 1 (AST1). GOT1 is a cytoplasmic enzyme critical in amino acid metabolism, catalyzing the reversible conversion of aspartate and α-ketoglutarate to oxaloacetate and glutamate. This reaction links the urea cycle with the tricarboxylic acid (TCA) cycle, playing a vital role in cellular energy production and nitrogen homeostasis.
GOT1 is highly expressed in tissues with active metabolic demands, such as the liver, heart, and kidneys. Its levels are clinically relevant as a biomarker for liver damage or myocardial infarction. In research, the GOT1 antibody is employed in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein expression, localization, and regulation. Studies focus on its involvement in diseases, including cancer, where altered GOT1 activity impacts tumor metabolism and progression.
Antibodies targeting GOT1 are typically developed in hosts like rabbits or mice, validated for specificity through knockdown/knockout controls. Researchers utilize these antibodies to explore GOT1's role in metabolic reprogramming, redox balance, and its potential as a therapeutic target. Understanding GOT1 function via antibody-based assays contributes to insights into metabolic disorders, cancer biology, and organ-specific pathologies.